With stem cells involved increasingly in the political debate, there was some positive news from California, where help Gov. Arnold Schwarzenegger, in the wake of the President veto a loan of up to $ 150 million for the California Institute for Regenerative Medicine fund initial research grants. Voters backed the institute was founded in 2004 by passing a statewide debt measure they the sale of up to sell up to $ 3 billion in state general obligation bonds to fund stem cell research. Nevertheless ongoing litigation against the measure has been. Prevent the sale of the bonds also added stem cell company Osiris Therapeutics Inc., the IPO runway sell us on 3000 shares in the range of $ 11 to $ 13.

Illumina shares closed July percent to 29.. Burrill Mid-Cap Biotech Index the mid-cap index remained at a relatively even keel thanks to the extraordinary performance illuminators whose shares have seen a meteoric rise of 171 percent since January. In July , the company announced that it formed a partnership with ReaMetrix diagnostics, to co-develop molecular diagnostic panels for a number of diseases ranges. Alnylam shares the terms of the agreement ReaMetrix will become non-exclusive rights to commercialize the resulting plates in India.The new technology is allow researchers to to determine whether the bacteria are resistant to antibiotics. To better treatments to better treatment strategy, well in pigs and humans. The researchers hope that that it is also result for the development of an effective vaccine.